

Molecular assay for C. diff, 8/17

August 2017—Quidel received 510(k) clearance to market its Solana *C. difficile* Assay for the direct, qualitative detection of *Clostridium difficile* DNA in unformed stool specimens of patients suspected of having *Clostridium difficile* infection.

The Solana *C. difficile* Assay is a molecular diagnostic test that generates results, without an upfront nucleic acid extraction step, in about 35 minutes.

The Solana molecular platform uses helicase-dependent amplification technology combined with fluorescence detection and can process up to 12 different assays or patient samples in each batched run.

[Quidel](#), 800-874-1517